NextCell Pharma AB

NXTCL

SE0009723125

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 20/06/2024 BST			5-day change	1st Jan Change
1.46 ^SEK	-3.31%		+2.82%	-44.49%

06-12	Nextcell Pharma AB Receives Positive Recommendation from Data Safety Monitoring Board for Protrans-Young Study	CI
05-28	NextCell Pharma AB Announces Single Treatment with ProTrans Demonstrates Long-Term Therapeutic Effect over 5 Years	CI

Diamyd Medical Proposes Anders Essen-Möller as New Chairman for Cellaviva AB

January 22, 2016 at 10:40 am

Diamyd announced that its CEO, Anders Essen-Möller is proposed as new Chairman of the Board of Cellaviva AB at Cellaviva's Annual General Meeting, February 18, 2016.

Latest news about NextCell Pharma AB

Nextcell Pharma AB Receives Positive Recommendation from Data Safety Monitoring Board for Protrans-Young Study	06-12	CI
NextCell Pharma AB Announces Single Treatment with ProTrans Demonstrates Long-Term Therapeutic Effect over 5 Years	05-28	CI
Nextcell Pharma AB Elects Hans-Peter Ekre as New Chairman of the Board	05-27	CI
NextCell Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	04-25	CI
NextCell Pharma AB Announces Swedish Health and Social Care Inspectorate Grants Their Cellaviva Tissue Establishment Permission to Handle Amniotic Tissue	04-22	CI
NextCell Pharma Chairman to Step Down in May	04-19	MT
Anders Essen-Möller Resigns as Chairman of NextCell Pharma AB	04-19	CI
The Swedish Medical Products Agency Approves Subgroup Analysis in NextCell Pharma AB's ProTrans-Young study	03-27	CI
NextCell Pharma AB Establishes QVance to Meet the Nordic's Need for Quality Analytics	03-14	CI
NextCell Pharma AB Reports Earnings Results for the First Quarter Ended November 30, 2023	01-25	CI
Nextcell Pharma Announces Updates Regarding Nextcell's Clinical Trials with Protrans	01-24	CI
NextCell Pharma AB Announces Repeated Treatment with ProTrans Is Immunologically Safe	11-06	CI
NextCell Pharma AB Reports Earnings Results for the Full Year Ended August 31, 2023	26/10/23	CI
NextCell Pharma AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	26/10/23	CI
Nextcell Pharma, Lino Signs Distribution Deal in Sweden	10/10/23	MT
Nextcell Pharma AB Signs an Agreement for A New Tissue Product with Linio	10/10/23	CI
NextCell Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	27/07/23	CI
NextCell Pharma Moves to Last Stage of Pneumonia Therapy Study	05/07/23	MT
NextCell Pharma AB Announces Treatment Start of Severe Pneumonia with High Dose of ProTrans	05/07/23	CI
NextCell Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	27/04/23	CI
FDA Approves a Product of Multiplied Stem Cells from Umbilical Cord Blood of NextCell Pharma AB	26/04/23	CI
Nextcell Pharma AB Publishes the Phase I/II Clinical Trial in Type I Diabetes Accepted	28/03/23	CI
NextCell Pharma AB Reports Earnings Results for the First Quarter Ended November 30, 2022	26/01/23	CI
Nextcell Pharma Receives Positive EMA Feedback on Pediatric Type 1 Diabetes Drug Plan	18/01/23	MT
NextCell Pharma AB Announces First Pediatric Patients Treated with ProTrans in Type-1 Diabetes Phase II Study	21/12/22	CI

NextCell Pharma AB, formerly Cellaviva AB, is a Sweden-based biopharmaceutical company. The Company is focusing on research and development of stem cell therapies and is also running a tissue establishment and biobank, classified as healthcare provider. NextCell's business concept is to develop and commercialize mesenchymal stem cell products based on the Company's proprietary selection algorithm, primarily for the treatment of autoimmune diabetes, as well as other types of autoimmune diseases.

Sector

Biotechnology & Medical Research

Calendar

24/07/2024 - Q3 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEXTCELL PHARMA AB	-44.49%	4.76M
MODERNA, INC.	+34.14%	51.12B
IQVIA HOLDINGS INC.	-6.54%	39.4B
LONZA GROUP AG	+34.92%	38.48B
CELLTRION, INC.	-12.11%	26.22B
ICON PUBLIC LIMITED COMPANY	+12.62%	26.36B
ALNYLAM PHARMACEUTICALS, INC.	-13.43%	20.96B
UNITED THERAPEUTICS CORPORATION	+43.73%	14.02B
MEDPACE HOLDINGS, INC.	+31.81%	12.49B
BIO-TECHNE CORPORATION	-4.54%	11.61B